Mills J C, Stone N L, Erhardt J, Pittman R N
Department of Pharmacology, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
J Cell Biol. 1998 Feb 9;140(3):627-36. doi: 10.1083/jcb.140.3.627.
The evolutionarily conserved execution phase of apoptosis is defined by characteristic changes occurring during the final stages of death; specifically cell shrinkage, dynamic membrane blebbing, condensation of chromatin, and DNA fragmentation. Mechanisms underlying these hallmark features of apoptosis have previously been elusive, largely because the execution phase is a rapid event whose onset is asynchronous across a population of cells. In the present study, a model system is described for using the caspase inhibitor, z-VAD-FMK, to block apoptosis and generate a synchronous population of cells actively extruding and retracting membrane blebs. This model system allowed us to determine signaling mechanisms underlying this characteristic feature of apoptosis. A screen of kinase inhibitors performed on synchronized blebbing cells indicated that only myosin light chain kinase (MLCK) inhibitors decreased blebbing. Immunoprecipitation of myosin II demonstrated that myosin regulatory light chain (MLC) phosphorylation was increased in blebbing cells and that MLC phosphorylation was prevented by inhibitors of MLCK. MLC phosphorylation is also mediated by the small G protein, Rho. C3 transferase inhibited apoptotic membrane blebbing, supporting a role for a Rho family member in this process. Finally, blebbing was also inhibited by disruption of the actin cytoskeleton. Based on these results, a working model is proposed for how actin/myosin II interactions cause cell contraction and membrane blebbing. Our results provide the first evidence that MLC phosphorylation is critical for apoptotic membrane blebbing and also implicate Rho signaling in these active morphological changes. The model system described here should facilitate future studies of MLCK, Rho, and other signal transduction pathways activated during the execution phase of apoptosis.
凋亡进化上保守的执行阶段由细胞死亡最后阶段发生的特征性变化所定义;具体表现为细胞皱缩、动态膜泡形成、染色质凝聚和DNA片段化。此前,凋亡这些标志性特征背后的机制一直难以捉摸,很大程度上是因为执行阶段是一个快速事件,其起始在一群细胞中是异步的。在本研究中,描述了一个模型系统,该系统使用半胱天冬酶抑制剂z-VAD-FMK来阻断凋亡,并产生一群同步的、正在积极挤出和回缩膜泡的细胞。这个模型系统使我们能够确定凋亡这一特征背后的信号传导机制。对同步化的膜泡形成细胞进行的激酶抑制剂筛选表明,只有肌球蛋白轻链激酶(MLCK)抑制剂能减少膜泡形成。肌球蛋白II的免疫沉淀表明,膜泡形成细胞中肌球蛋白调节轻链(MLC)的磷酸化增加,并且MLCK抑制剂可阻止MLC磷酸化。MLC磷酸化也由小G蛋白Rho介导。C3转移酶抑制凋亡膜泡形成,支持Rho家族成员在此过程中的作用。最后,肌动蛋白细胞骨架的破坏也抑制了膜泡形成。基于这些结果,提出了一个关于肌动蛋白/肌球蛋白II相互作用如何导致细胞收缩和膜泡形成的工作模型。我们的结果首次证明MLC磷酸化对凋亡膜泡形成至关重要,并且还表明Rho信号传导参与了这些活跃的形态变化。这里描述的模型系统应有助于未来对MLCK、Rho以及凋亡执行阶段激活的其他信号转导途径的研究。